# Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

> **NCT04283669** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 12 (actual)

## Conditions studied

- Neurofibromatosis 2
- Progressive Vestibular Schwannoma (VS)

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT04283669
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-18
- **Primary completion:** 2025-02-25
- **Final completion:** 2025-02-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283669, "Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04283669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*